A study in Stroke showed that type 2 diabetes patients who used canagliflozin had a significant reduction in hemorrhagic stroke, which could be mediated by reduced blood pressure, compared with placebo. Australian researchers analyzed data from the CANVAS Program involving 10,142 diabetes patients with high cardiovascular risk and found comparable proportional effects of canagliflozin on CV, kidney and mortality outcomes among those with and without cerebrovascular disease at baseline, compared with placebo.
Canagliflozin may reduce hemorrhagic stroke risk in diabetes
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.